Doctors say they’re filling a void left by CDC on vaccines. Here’s what to know about flu, Covid-19 and RSV this fall

Medical Groups Step In as CDC Goes Quiet on Fall Vaccine Guidance

Activelifezero.com – As classrooms refill and autumn air carries the familiar warning of respiratory season, millions of Americans face a question that has no clear federal answer this year: which vaccines should they get, and when? For decades, the Centers for Disease Control and Prevention has anchored the fall immunization calendar with explicit seasonal recommendations. In 2026, that anchor has slipped. The agency has not published new guidance for RSV immunization or updated Covid-19 vaccines for the coming season, leaving clinicians, parents, and older adults to navigate a landscape of uncertainty.

The silence is not accidental. Under the second Trump administration, the CDC has largely withdrawn from its traditional role as the nation’s primary voice on vaccine scheduling. Last year, the agency walked back a broad recommendation for annual Covid-19 vaccination, replacing it with language telling patients to “consult with a healthcare provider” before receiving the shot. This year, the retreat has deepened. On Tuesday, the CDC posted a brief update to its flu-shot guidance page, stating that the recommendations embedded in the July 2025 immunization schedule “remain in effect for the 2026-2027 influenza season.” Notably, that update makes no mention of the first mRNA-based flu vaccine, which the Food and Drug Administration approved last month specifically for older adults.

Independent Reviews Fill the Gap

With the federal pipeline stalled, two organizations moved to close the gap. The American Medical Association and the University of Minnesota’s Vaccine Integrity Project conducted parallel, independent evidence reviews covering this fall’s flu, Covid-19, and RSV vaccines. Their findings were published Wednesday in the peer-reviewed journal JAMA. Those reviews, in turn, fed directly into coordinated 2026-27 respiratory-virus immunization recommendations issued the same day by a coalition of major specialty societies: the American Academy of Pediatrics, the American Academy of Family Physicians, the American College of Obstetricians and Gynecologists, and the Infectious Diseases Society of America.

The recommendations lay out, in practical terms, which vaccines are advised for which populations and the optimal timing for administration. Flu and RSV immunizations are already on pharmacy shelves across the country, and newly updated Covid-19 formulations have recently cleared FDA review and are entering distribution. Insurance carriers, according to the briefing, have signaled to the major medical groups that they will cover these respiratory-virus immunizations, removing a common financial barrier for patients.

“We Cannot Allow a Vacuum”

Dr. Bruce Gellin, board chair of the Vaccine Integrity Project and professor of medicine at Georgetown University, framed the situation bluntly at a Wednesday news briefing:

“For more than 60 years, the United States has benefited from an established federal process for evaluating vaccine evidence and translating that science into recommendations for the American public. At the center of that process were the Centers for Disease Control and its Advisory Committee on Immunization Practices, the ACIP. Unfortunately today, the federal government is not fulfilling that responsibility in the way that it historically has. But the need for that work has not disappeared. Influenza, SARS-CoV-2 and the RSV viruses will circulate again this fall and winter. Clinicians will still have patients to care for. Parents will still have decisions to make for their children, and older Americans, pregnant women and people with underlying health conditions will still need to know how best to protect themselves. We cannot allow the breakdown of a federal process to create a vacuum in evidence-based vaccine guidance.”

The concern extends beyond scheduling logistics. Physicians expressed alarm that a recent executive order signed by President Trump could further erode public confidence in vaccination, steering families away from immunizations during precisely the season when respiratory viruses peak. Without a unified federal message, the risk of confusion—and of preventable hospitalizations—rises.

What the Recommendations Say

For RSV, the guidance identifies three eligible groups: older adults, pregnant individuals, and infants. Dr. Sarah Nosal, president of the American Academy of Family Physicians, clarified the dosing question many patients will ask:

“People age 50 and older with high-risk conditions, and everyone over 75 years old, should get one dose. This is not an annual vaccine. If you got one before, you do not need a new one this year. Getting one should protect you throughout the entire season.”

During pregnancy, RSV vaccination is recommended to pass protective antibodies to the newborn, shielding the infant during the first months of life when its own immune system is still maturing. The flu recommendation, anchored to the July 2025 schedule, continues to advise annual vaccination for essentially everyone six months and older, with particular urgency for those over 65, pregnant women, and individuals with chronic cardiopulmonary or metabolic conditions. Updated Covid-19 formulations, tailored to circulating variants, are advised for adults at elevated risk of severe disease, with the final decision framed as a shared conversation between patient and provider.

“Vaccines are one of medicine’s greatest success stories. They prevent serious illness, reduce hospitalizations and long-term complications and save lives. As federal guidance evolves, the science behind vaccines remains strong. These recommendations are grounded in the latest evidence, informed by public health experts and shaped by what family physicians are seeing every day in their patients.”

The US Department of Health and Human Services did not respond to requests for comment on the groups’ recommendations.

Why This Matters Beyond the Pharmacy Counter

The episode underscores a structural vulnerability: when a single federal agency holds a near-monopoly on translating immunization science into public guidance, any pause in that function creates an immediate information vacuum. The coordinated response by specialty societies this week demonstrates that the medical community can mobilize quickly, but it also highlights that the burden of keeping the public informed now falls on a patchwork of professional organizations rather than on a single, authoritative public-health voice. For patients, the practical takeaway is straightforward—talk to your doctor about which of this season’s vaccines apply to you, confirm insurance coverage before your visit, and do not let the absence of a federal headline be mistaken for the absence of risk. The viruses do not check government press releases before they circulate.